Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Metadata
Title
Refining muromonab CD3 administration can reduce adverse effects
Publication date
01-01-2000
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 2/2000
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.2165/00042310-200015020-00002

Other articles of this Issue 2/2000

Drugs & Therapy Perspectives 2/2000 Go to the issue

Drug reactions and interactions

Visual field defects with vigabatrin: an unforeseen problem?

New drugs and disease management

Time is of the essence when treating acute ischaemic stroke

New drugs and disease management

Chemoprotectants ameliorate chemotherapy-associated toxicity at specific sites

New drugs and disease management

Rofecoxib: a selective COX-2 inhibitor